- Home
- VANI vs IPSC Comparison
VANI vs IPSC Comparison
Compare VANI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- IPSC
- Stock Information
- Founded
- VANI 1998
- IPSC 2019
- Country
- VANI United States
- IPSC United States
- Employees
- VANI N/A
- IPSC N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- VANI Health Care
- IPSC Health Care
- Exchange
- VANI Nasdaq
- IPSC Nasdaq
- Market Cap
- VANI 69.3M
- IPSC 62.1M
- IPO Year
- VANI 2014
- IPSC 2021
- Fundamental
- Price
- VANI $1.15
- IPSC $0.73
- Analyst Decision
- VANI Strong Buy
- IPSC Strong Buy
- Analyst Count
- VANI 1
- IPSC 5
- Target Price
- VANI $3.00
- IPSC $11.00
- AVG Volume (30 Days)
- VANI 83.2K
- IPSC 493.4K
- Earning Date
- VANI 03-25-2025
- IPSC 03-13-2025
- Dividend Yield
- VANI N/A
- IPSC N/A
- EPS Growth
- VANI N/A
- IPSC N/A
- EPS
- VANI N/A
- IPSC N/A
- Revenue
- VANI N/A
- IPSC $2,684,000.00
- Revenue This Year
- VANI N/A
- IPSC $230.60
- Revenue Next Year
- VANI N/A
- IPSC $31.83
- P/E Ratio
- VANI N/A
- IPSC N/A
- Revenue Growth
- VANI N/A
- IPSC 7.88
- 52 Week Low
- VANI $1.01
- IPSC $0.68
- 52 Week High
- VANI $7.80
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- VANI 43.02
- IPSC 30.98
- Support Level
- VANI $1.12
- IPSC $0.72
- Resistance Level
- VANI $1.19
- IPSC $0.82
- Average True Range (ATR)
- VANI 0.03
- IPSC 0.06
- MACD
- VANI 0.00
- IPSC 0.01
- Stochastic Oscillator
- VANI 42.86
- IPSC 27.43
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.